Record Quarterly Sales
Second quarter record sales of $741 million, up 8% year-over-year, including 7% organic growth and a 3% favorable currency translation impact.
Strong Order Momentum and Backlog Growth
Backlog increased 18% organically year-over-year, with order entry momentum broad-based across all three segments, supporting confidence in near-term demand.
Record EBITDA and Margin Performance
EBITDA reached a second-quarter record of $235 million (32% of sales), up 8% year-over-year; adjusted operating profit was $199 million (27% of sales), up 11% year-over-year.
Record Adjusted Earnings Per Share
Adjusted EPS of $2.86 was a second-quarter record and rose 18% year-over-year (from $2.42); GAAP net income was $117 million, or $2.09 per share.
Exceptional Cash Generation and Conversion
Free cash flow of $170 million in the quarter with conversion of ~119% of net income (excluding noncash losses); enabled dividends of $46 million, $43 million of share repurchases, $10 million of capex, and $93 million net debt reduction.
Healthy Balance Sheet and Lower Leverage
Cash on hand of $102 million and net debt of ~$1.8 billion; net leverage ratio improved to 1.9x, now below the low end of the company's long-term target range.
Strategic Small Acquisition — CapstanAG
Acquired CapstanAG (precision agriculture) for ~9x adjusted EBITDA to expand North American precision agriculture capabilities and strengthen mid-tier OEM presence; acquisition is bolt-on strategic fit.
Segment Records and Broad-Based Growth
All three segments posted second-quarter records: Industrial Precision Solutions sales $350M (+10% YoY; organic +5%), Medical & Fluid Solutions $213M (+5% YoY; organic +8%), Advanced Technology Solutions $178M (+10% YoY; organic +8%).
Outstanding ATS Performance
Advanced Technology Solutions set an all-time quarterly record: EBITDA $48M (27% margin), a 22% increase versus prior-year EBITDA of $40M, driven by electronics dispense strength and semiconductor demand.
Improved Interest and Tax Outlook
Net interest expense decreased to $22 million (down $4 million YoY); adjusted effective tax rate of ~18% with full-year adjusted tax guidance narrowed to 18%–19%, slightly better than prior expectations.